Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis
, Marta Peri 3, Giuseppe Roberto Giammalva 4, Antonino Lupica 1, Federica Paolini 4, Lorena Incorvaia 3, Giuseppe Badalamenti 3, Valerio Gristina 3, Antonio Galvano 3, Antonio Russo 3, Domenico Gerardo Iacopino 4, Mauro Silvestrini 2, Viviana Bazan 5,†, Filippo Brighina 1,†and Vincenzo Di Stefano 1,*,†
Round 1
Reviewer 1 Report
Good review. Just some minor comments in the attached pdf file.
Comments for author File: 
Comments.pdf
Author Response
Dear Editors and Reviewers
Thanks for your comments. We would like to submit our revised version of the manuscript for possible publication in Diagnostics.
Reviewer 1: Good review. Just some minor comments in the attached pdf file.
Line 89: Programmed Death-Ligand 1 (PD-L1). What do the opposite results show?
R: We explained deeply this concept. The sentence “opposite results” is related to the heterogeneity of the literature about this topic due to paucity of data
Line 93. For example, high dietary phosphate intake stimulates PI3K/AKT/mTOR in tumorigenesis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615662/
R: thank you for the comment
Line 114. multiple lesions from the beginning.
R: thank you for this suggestion.
Line 230. IFN-γ
R: thank you for this suggestion.
Line 327. Postulate
R: thank you for this suggestion.
Hoping in positive feedback we look forward to hearing from you soon.
Kind regards,
Vincenzo Di Stefano
Reviewer 2 Report
A good review however some suggestions to improve the manuscript:
1. Figure 1: Please include what is Figure 1A, 1B and 1C in the description.
2. Line 81: Please further elaborate on how HIF has become a promising therapeutic target.
3. Line 89-90: Please explain this sentence, what are the opposite results?
4. Line 222: reference no.51 - does not follow the format
4. Line 297: References for Thl7 cells and IL-17 are linked to MG pro- 297 gress?
5. Figure 2: The whole figure should be seen in the manuscript.
Author Response
Dear Editors and Reviewers
Thanks for your comments. We would like to submit our revised version of the manuscript for possible publication in Diagnostics.
Reviewer 2: A good review however some suggestions to improve the manuscript:
1. Figure 1: Please include what is Figure 1A, 1B and 1C in the description.
R: thank you for this suggestion. It was revised in the last version of the manuscript.
2. Line 81: Please further elaborate on how HIF has become a promising therapeutic target.
R: Considering the reviewer’s request, we added a more detailed description of HIF therapeutical role.
3. Line 89-90: Please explain this sentence, what are the opposite results?
R: We explained deeply this concept. The sentence “opposite results” is related to the heterogeneity of the literature about this topic due to paucity of data
4. Line 222: reference no.51 - does not follow the format
R: thank you for this suggestion. It was revised in the last version of the manuscript.
5. Line 297: References for Thl7 cells and IL-17 are linked to MG progress?
R: thank you for this suggestion. IL-17 knock-out mice, authors detected reduced myasthenia symptoms and large decreases in anti-AChR antibodies, suggesting that IL-17 regulated the B-cells antibody generation, and supporting the involvement of Th17 cells in MG autoimmunity. We still do not know if IL-17 might be linked to MG progressing.
6. Figure 2: The whole figure should be seen in the manuscript.
R: thank you for this suggestion. The figure was revised in the last version of the manuscript.
Hoping in positive feedback we look forward to hearing from you soon.
Kind regards,
Vincenzo Di Stefano
